|Awarded On||February 19, 2020|
|Title||CRAD Tumor Suppressor and Mucinous Adenocarcinoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Jae-Il Park|
|Cancer Sites||Colorectal, Stomach|
*Pending contract negotiation
Mucinous adenocarcinoma (MAC) is therapeutically resistant and highly metastatic, with poor patient outcomes. However, the molecular basis of MAC remains elusive. Moreover, neither mouse models or biomarkers for premalignant MAC are present, and therapeutic options are limited. Thus, it is imperative to understand the pathobiology of MAC and to develop therapeutic applications for treatment and prevention of MAC. The proposed study will dissect the cellular and molecular mechanisms of mucinous tumorigenesis and use that knowledge to develop therapeutic and preventive approaches for MAC. Recently, the principal investigator (PI) identified a new tumor suppressor, called CRAD (Cancer-related R...